A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Latest Information Update: 24 May 2024
At a glance
- Drugs Lumasiran (Primary)
- Indications Renal calculi
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
Most Recent Events
- 20 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2021 to 1 Jan 2022.